WAM
MACK

Wolverine Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Wolverine Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,495
Closed -$34K – 1595
2017
Q2 		$34K Sell
3,495
-9,393
-73% -$192K ﹤0.01% 1155
2017
Q1 		$312K Buy
12,888
+6,292
+95% +$157K ﹤0.01% 790
2016
Q4 		$211K Buy
6,596
+5,300
+409% +$226K ﹤0.01% 822
2016
Q3 		$64K Buy
+1,296
New +$53.8K ﹤0.01% 1022
2015
Q4 		– Sell
-7
Closed -$4K – 2047
2015
Q3 		$4K Buy
+7
New +$571 ﹤0.01% 1680
2015
Q2 		– Sell
-76
Closed -$28K – 2116
2015
Q1 		$28K Sell
76
-13
-15% -$1.11K ﹤0.01% 1384
2014
Q4 		$82K Sell
89
-130
-59% -$9.47K ﹤0.01% 1261
2014
Q3 		$49K Sell
219
-194
-47% -$10.4K ﹤0.01% 1537
2014
Q2 		$210K Buy
413
+327
+380% +$16.6K ﹤0.01% 906
2014
Q1 		$82K Buy
86
+58
+207% +$2.48K ﹤0.01% 1189
2013
Q4 		$5K Buy
+28
New +$812 ﹤0.01% 2377

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wolverine Asset Management's MACK Position: Q2 2014 in Review

Wolverine Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2014, closing a stake of 534 shares — an estimated $27.1K sold.

Wolverine Asset Management first reported a position in MACK in Q1 2014 and held it in 1 quarter. The position peaked at $21K in Q1 2014. 121 funds tracked by Wall St. Rank hold MACK as of Q2 2014.

  • Wolverine Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Wolverine Asset Management sold 534 Merrimack Pharmaceuticals, Inc. shares in Q2 2014, an estimated $27.1K.
  • Wolverine Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Wolverine Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $21K in Q1 2014.
  • 121 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2014.

Based on Wolverine Asset Management's 13F filing for Q2 2014, filed 13 Aug 2014.